Sign in
TerminatedPhase 1/2

Prostate Cancer Vaccines

Key facts

Who runs it
Shenzhen Geno-Immune Medical Institute
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 1/2
People taking part
30 people enrolled
Started
15 Jun 2025
Ended
31 Jul 2026
Type of study
Interventional
Treatments tested
  • Immunomodulatory DC vaccines to target prostate cancer
Record updated
2 November 2026

Who can take part

Age
18 years to 80 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Histologically confirmed adenocarcinoma of the prostate
  • ECOG performance status 0-1
  • Life expectancy ≥ 12 weeks
  • WBC ≥ 3,500/µL
  • Platelet count ≥ 100,000/µL
  • Hemoglobin ≥ 10.0 g/dL
  • Creatinine ≤ 2.0 mg/dL
  • Alkaline phosphatase ≤ 2.5 times upper limit of normal (ULN)
  • AST ≤ 2.5 times ULN
  • Fertile patients must use effective contraception
  • Willing to provide blood samples for research purposes
  • Able to complete questionnaire(s) alone or with assistance
  • Able to undergo leukapheresis
  • No known immunodeficiency
  • No other malignancy within the past 5 years except for basal cell or squamous cell carcinoma of the skin treated with local resection only
  • No concurrent serious illness
  • No known history of positive PPD skin test
  • Human immunodeficiency virus (HIV) and Hepatitis C virus (HCV) test negative

Who cannot take part

  • The patient was still using dexamethasone at a dose greater than 4 mg/day during mononuclear cell collection
  • Patients who had previously been treated with cell therapy products and examined by team experts deemed not suitable for treatment
  • Patients have a history of autoimmune diseases or other diseases requiring long-term use of hormones or immunosuppressive drugs
  • Patients with a history of allergies or allergies to immune cells and adjuvants of cellular products
  • Active infection with fever
  • Infection with bacteria, fungi or viruses, uncontrolled
  • Patients with HIV and those living with active HBV and HCV
  • Severe organ failure (heart, liver, kidney, lung)
  • Patients with neutropenia (> 10 days) that are difficult to correct after treatment
  • Anything that researchers believe may increase the risk of subjects or interfere with test results

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Tumor antigens are protein fragments produced by cancer cells carrying genetic mutations, and many tumor antigens are similar to normal protein antigens, making them unrecognizable by the immune system. Many tumor vaccines are prepared based on a single tumor antigen. This study is based on multiple target antigens using tumor lysates or synthetic peptides. The immune modulation by dendritic-cell (DC)-based cancer vaccines consists of genetically modified DCs to activate T cells to target cancer cells. The study is based on an advanced cancer vaccine technology, which aims to evaluate the safety and potential benefit of the novel immunomodulatory prostate cancer DC vaccines.

The group in the trial

  • Experimental: Immunomodulatory DC vaccines to target prostate cancerTreatment being tested

    Prostate tumor antigen-modified autologous DCs

    Treatment: Immunomodulatory DC vaccines to target prostate cancer

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Development of Prostate Cancer Dendritic Cell Vaccines
Record updated
2 November 2026